Benchmarking, accountability, bilateralism, and scalability are the 4 parameters critical to successful alternative payment models in oncology, said Aaron Lyss, MBA, director of strategy and business development at Tennessee Oncology.
Benchmarking, accountability, bilateralism, and scalability are the 4 parameters critical to successful alternative payment models in oncology, said Aaron Lyss, MBA, director of strategy and business development at Tennessee Oncology.
Transcript:
What would you like to see in the next iteration of a payment model for oncology?
I think there are 4 parameters that are critical to alternative payment models in oncology. The first is benchmarking. Are the performance benchmarks associated with the model achievable and reasonable for the practices who are participating? I think the second important issue is control and accountability. By that,I mean, does a practice, do providers have control over the outcomes of the model? Can they then be held accountable for their performance? Then I think the third issue is what I'll refer to as bilateralism. That's basically, is the payment structure of the model suitable both to the provider group as well as to the payer, based on the value that the practice can create in the model? Then the fourth issue is scalability. Does the model apply to a broad enough population of patients that enables the practice to focus on all the improvements in care delivery that they want to see across a very broad population? Then from the payer perspective, does the model work for a broad enough population of practices that it can apply to a nationwide cohort of practices who would be participating?
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025
March 13th 2025Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
Read More